Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2)

Chengqiang Li, Yichao Han, Shengguang Zhao, Xiaozheng Kang, Yuyan Zheng, Yuqin Cao, Yan Yan, Liqiang Shi, Xipeng Wang, Tong Lu, Guowen Zou, Huan Li, Jiaming Che, Jie Xiang, Lianggang Zhu, Junbiao Hang, Yajie Zhang, Runsen Jin, Dingpei Han, Xueyu Chen, Hui Jing, Wei Guo, Zenghui Cheng, Liqin Zhao, Xiaoyan Chen, Bentong Yu, Jian Li, Bin Li, Yin Li, Hecheng Li

Open source

DOI: 10.1038/s41392-025-02477-4
Published: 2025-11-28
Container: Signal Transduction and Targeted Therapy
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41392-025-02477-4,
  title = {Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2)},
  author = {Chengqiang Li and Yichao Han and Shengguang Zhao and Xiaozheng Kang and Yuyan Zheng and Yuqin Cao and Yan Yan and Liqiang Shi and Xipeng Wang and Tong Lu and Guowen Zou and Huan Li and Jiaming Che and Jie Xiang and Lianggang Zhu and Junbiao Hang and Yajie Zhang and Runsen Jin and Dingpei Han and Xueyu Chen and Hui Jing and Wei Guo and Zenghui Cheng and Liqin Zhao and Xiaoyan Chen and Bentong Yu and Jian Li and Bin Li and Yin Li and Hecheng Li},
  year = {2025},
  journal = {Signal Transduction and Targeted Therapy},
  doi = {10.1038/s41392-025-02477-4},
  url = {https://doi.org/10.1038/s41392-025-02477-4}
}

RIS

TY  - JOUR
TI  - Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2)
AU  - Chengqiang Li
AU  - Yichao Han
AU  - Shengguang Zhao
AU  - Xiaozheng Kang
AU  - Yuyan Zheng
AU  - Yuqin Cao
AU  - Yan Yan
AU  - Liqiang Shi
AU  - Xipeng Wang
AU  - Tong Lu
AU  - Guowen Zou
AU  - Huan Li
AU  - Jiaming Che
AU  - Jie Xiang
AU  - Lianggang Zhu
AU  - Junbiao Hang
AU  - Yajie Zhang
AU  - Runsen Jin
AU  - Dingpei Han
AU  - Xueyu Chen
AU  - Hui Jing
AU  - Wei Guo
AU  - Zenghui Cheng
AU  - Liqin Zhao
AU  - Xiaoyan Chen
AU  - Bentong Yu
AU  - Jian Li
AU  - Bin Li
AU  - Yin Li
AU  - Hecheng Li
PY  - 2025
JO  - Signal Transduction and Targeted Therapy
DO  - 10.1038/s41392-025-02477-4
UR  - https://doi.org/10.1038/s41392-025-02477-4
ER  -

APA

Li, C., Han, Y., Zhao, S., Kang, X., Zheng, Y., Cao, Y., Yan, Y., Shi, L., Wang, X., Lu, T., Zou, G., Li, H., Che, J., Xiang, J., Zhu, L., Hang, J., Zhang, Y., Jin, R., Han, D., Chen, X., Jing, H., Guo, W., Cheng, Z., Zhao, L., Chen, X., Yu, B., Li, J., Li, B., Li, Y., & Li, H. (2025). Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2). Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-025-02477-4

Source records

crossref · retrieved 2026-09-25T14:13:41.268Z